Abstract
Background
Thyroid eye disease (TED) presents a management dilemma for strabismologists due to the variability of its clinical course. Prisms may be prescribed to relieve diplopia in small deviations. Surgical intervention, on the other hand, should not be done until the active phase of the disease has subsided. We report our experience with chemodenervation utilizing botulinum toxin (BT) injection in the management of TED-related strabismus.
Methods
A retrospective chart review was done on twenty-two (22) consecutive patients receiving BT injections at the University of California, San Diego (UCSD) Thyroid Eye Center. All BT injections were administered by a single physician under electromyographic guidance.
Results
The clinical records of 22 patients (18 females) were reviewed. Seven patients (32 %) had a reduction of their deviation to a point where surgery was not required. In six patients (27 %), surgery was required but an improvement in ocular deviation was found, altering the original surgical plan. In four patients (18 %), the deviation continued to progress after BT injection. Success rates were higher if pre-treatment deviation was less than 20 prism diopters (∆).
Conclusion
One third of the chemodenervation-treated patients avoided surgical intervention, with an additional 27 % (total of 40 % of those who needed surgery) having a reduced deviation prior to surgery. Using BT injection to extraocular muscles to treat diplopia in TED patients is most effective in preventing surgery in those patients with 20∆ or less of deviation.
Similar content being viewed by others
References
Granet DB (2011) Strabismus: aligning the doctor’s vision with the patient’s need. Br J Ophthalmol 95:443–444. doi:10.1136/bjo.2010.188326
Phillips ME, Marzban MM, Kathuria SS (2010) Treatment of thyroid eye disease. Curr Treat Options Neurol 12:64–69. doi:10.1007/s11940-009-0054-0
Verity DH, Rose GE (2013) Acute thyroid eye disease (TED): principles of medical and surgical management. Eye (Lond) 27:308–319. doi:10.1038/eye.2012.284
Marcocci C, Marino M (2012) Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab 26:325–337. doi:10.1016/j.beem.2011.11.005
Pillar AJ, Richa DC (2014) Treatment options for thyroid eye disease. Curr Treat Options Neurol 16:303. doi:10.1007/s11940-014-0303-8
Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM (2005) The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye (Lond) 19:1286–1289. doi:10.1038/sj.eye.6701768
Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P (2007) Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156:33–40. doi:10.1530/eje.1.02325
Scott AB (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87:1044–1049
Scott AB (1981) Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 79:734–770
Scott AB (1984) Injection treatment of endocrine orbital myopathy. Doc Ophthalmol 58:141–145
Dunn WJ, Arnold AC, O’Connor PS (1986) Botulinum toxin for the treatment of dysthyroid ocular myopathy. Ophthalmology 93:470–475
Wu X, Lin N, Ai LK, Wang JH, Yan LJ (2006) The application of botulinum toxin A in the treatment of restrictive strabismus in thyroid associated ophthalmopathy]. [Zhonghua yan ke za zhi] Chin J Pphthalmol 42:1063–1067
Kowal L, Wong E, Yahalom C (2007) Botulinum toxin in the treatment of strabismus. A review of its use and effects. Disabil Rehabil 29:1823–1831. doi:10.1080/09638280701568189
Gair EJ, Lee JP, Khoo BK, Maurino V (1999) What is the role of botulinum toxin in the treatment of dysthyroid strabismus? J AAPOS 3:272–274
Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA (1996) Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:284–290
Heufelder AE (2000) Pathogenesis of ophthalmopathy in autoimmune thyroid disease. Rev Endocr Metab Disord 1:87–95
Bahn RS (2010) Graves’ ophthalmopathy. N Engl J Med 362:726–738. doi:10.1056/NEJMra0905750
Smith TJ, Bahn RS, Gorman CA (1989) Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev 10:366–391. doi:10.1210/edrv-10-3-366
Dagi LR, Elliott AT, Roper-Hall G, Cruz OA (2010) Thyroid eye disease: honing your skills to improve outcomes. J AAPOS 14:425–431. doi:10.1016/j.jaapos.2010.07.005
Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R (1989) Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 73:639–644
Lyons CJ, Vickers SF, Lee JP (1990) Botulinum toxin therapy in dysthyroid strabismus. Eye (Lond) 4(Pt 4):538–542. doi:10.1038/eye.1990.74
Dawson EL, Sainani A, Lee JP (2005) Does botulinum toxin have a role in the treatment of secondary strabismus?*. Strabismus 13:71–73. doi:10.1080/09273970590935048
McNeer KW (1989) Botulinum toxin injection into the superior rectus muscle of the non-dominant eye for dissociated vertical deviation. J Pediatr Ophthalmol Strabismus 26:162–164
Bittencourt MK, de Vasconcellos JP, Bittencourt MD, Malago R, Bacellar M (2013) Evaluation of the efficacy and safety of botulinum toxin type A to induce temporary ptosis in dogs. J Ocul Pharmacol Ther 29:431–436. doi:10.1089/jop.2012.0119
Dintelmann T, Sold J, Grehn F (2005) Botulinum toxin injection-treatment of upper lid retraction in thyroid eye disease. Ophthalmologe 102:247–250. doi:10.1007/s00347-004-1091-4
Korn BS, Seo SW, Levi L, Granet DB, Kikkawa DO (2007) Optic neuropathy associated with botulinum A toxin in thyroid-related orbitopathy. Ophthal Plast Reconstr Surg 23:109–114. doi:10.1097/IOP.0b013e318032eb12
Taylan Sekeroglu H, Kocabeyoglu S, Mocan MC, Muz E, Karakaya J, Irkec M, Sanac AS (2014) Ocular surface changes following botulinum toxin injection for strabismus. Cutan Ocul Toxicol 1–4 Doi: 10.3109/15569527.2014.941996
Kikkawa DO, Cruz RC Jr, Christian WK, Rikkers S, Weinreb RN, Levi L, Granet DB (2003) Botulinum A toxin injection for restrictive myopathy of thyroid-related orbitopathy: effects on intraocular pressure. Am J Ophthalmol 135:427–431
Ohtsuka K, Nakamura Y (2000) Open-angle glaucoma associated with Graves disease. Am J Ophthalmol 129:613–617
Acknowledgments
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding was received for this research.
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.
Ethical approval
All procedures performed in this study were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
For this type of study formal consent is not required. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.
Rights and permissions
About this article
Cite this article
Granet, D.B., Hodgson, N., Godfrey, K.J. et al. Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease. Graefes Arch Clin Exp Ophthalmol 254, 999–1003 (2016). https://doi.org/10.1007/s00417-016-3281-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-016-3281-6